Recursion Pharmaceuticals, Inc. (RXRX)
RXRX Stock Price Chart
Explore Recursion Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze RXRX price movements and trends.
RXRX Company Profile
Discover essential business fundamentals and corporate details for Recursion Pharmaceuticals, Inc. (RXRX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
16 Apr 2021
Employees
800.00
Website
https://www.recursion.comCEO
Christopher C. Gibson
Description
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
RXRX Financial Timeline
Browse a chronological timeline of Recursion Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 26 Feb 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is -$0.35, while revenue estimate is $19.36M.
Earnings released on 5 Aug 2025
EPS came in at -$0.41 falling short of the estimated -$0.35 by -17.14%, while revenue for the quarter reached $19.10M , missing expectations by -4.13%.
Earnings released on 5 May 2025
EPS came in at -$0.50 falling short of the estimated -$0.44 by -13.64%, while revenue for the quarter reached $14.75M , beating expectations by +5.62%.
Earnings released on 28 Feb 2025
EPS came in at -$0.53 falling short of the estimated -$0.44 by -20.45%, while revenue for the quarter reached $4.51M , missing expectations by -76.31%.
Earnings released on 6 Nov 2024
EPS came in at -$0.34 falling short of the estimated -$0.33 by -3.03%, while revenue for the quarter reached $26.08M , beating expectations by +43.53%.
Earnings released on 8 Aug 2024
EPS came in at -$0.40 falling short of the estimated -$0.35 by -14.29%, while revenue for the quarter reached $14.42M , beating expectations by +8.73%.
Earnings released on 9 May 2024
EPS came in at -$0.39 surpassing the estimated -$0.43 by +9.30%, while revenue for the quarter reached $13.79M , beating expectations by +9.04%.
Earnings released on 27 Feb 2024
EPS came in at -$0.40 surpassing the estimated -$0.46 by +13.04%, while revenue for the quarter reached $10.89M , missing expectations by -46.48%.
Earnings released on 9 Nov 2023
EPS came in at -$0.43 falling short of the estimated -$0.38 by -13.16%, while revenue for the quarter reached $10.10M , missing expectations by -50.79%.
Earnings released on 8 Aug 2023
EPS came in at -$0.38 matching the estimated -$0.38, while revenue for the quarter reached $11.02M , missing expectations by -7.51%.
Earnings released on 8 May 2023
EPS came in at -$0.34 matching the estimated -$0.34, while revenue for the quarter reached $12.13M , missing expectations by -15.97%.
Earnings released on 27 Feb 2023
EPS came in at -$0.31 falling short of the estimated -$0.15 by -106.67%, while revenue for the quarter reached $13.68M , missing expectations by -42.54%.
Earnings released on 8 Nov 2022
EPS came in at -$0.35 surpassing the estimated -$0.36 by +2.78%, while revenue for the quarter reached $13.05M , beating expectations by +90.74%.
Earnings released on 9 Aug 2022
EPS came in at -$0.38 falling short of the estimated -$0.35 by -8.57%, while revenue for the quarter reached $7.65M , beating expectations by +43.49%.
Earnings released on 10 May 2022
EPS came in at -$0.33 falling short of the estimated $0.51 by -164.71%, while revenue for the quarter reached $5.30M , missing expectations by -93.69%.
Earnings released on 23 Mar 2022
EPS came in at -$0.38 falling short of the estimated -$0.30 by -26.67%, while revenue for the quarter reached $2.50M , missing expectations by -58.56%.
Earnings released on 10 Nov 2021
EPS came in at -$0.28 matching the estimated -$0.28, while revenue for the quarter reached $2.50M , missing expectations by -1.34%.
Earnings released on 13 Aug 2021
EPS came in at -$0.31 falling short of the estimated -$0.23 by -34.78%, while revenue for the quarter reached $2.50M , missing expectations by -1.92%.
Earnings released on 12 May 2021
EPS came in at -$0.18 , while revenue for the quarter reached $2.50M .
Earnings released on 16 Apr 2021
EPS came in at -$0.15 , while revenue for the quarter reached $2.55M .
Earnings released on 30 Sept 2020
EPS came in at -$0.14 , while revenue for the quarter reached $862.00K .
RXRX Stock Performance
Access detailed RXRX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.